Profile

Education
1984, M.D., Medical College of Zhejiang University
Medical student in the Department of Medicine (1979-1984), Zhejiang Medical University (now Medical College of Zhejiang University),
Hangzhou, China
1990, M.Sc., Medical College of Zhejiang University
Candidate for master of science (1987-1990), Department of Hematology, Medical College of Zhejiang University, Hangzhou, China
2000, Ph.D., Medical College of Zhejiang University
PhD candidate (1997-2000), Department of Hematology, Medical College of Zhejiang University, Hangzhou, China

Society Membership
Member: Hematology Committee, Chinese Medical Association, China.
Vice Chair: Hematology Committee, Chinese Medical Association, Zhejiang Branch, China.
Secretary: Hematology Committee, Chinese Anti-Cancer Association, China.
Vice Chair and Secretary: Chinese Anti-Cancer Association, Zhejiang Branch, China.
Vice Director: Hemato-Immunology Committee, Chinese Society of Immunology, Zhejiang Branch, China.

Academic Appointments:Aug. 1984-Oct. 1985
Resident, General Medicine, Department of General Medicine, Medical College of Zhejiang University, Hangzhou, China
Oct. 1985-Aug. 1990
Resident/Master Degree Candidate, Clinical Hematology, Department of Hematology, Medical College of Zhejiang University, Hangzhou, China
Aug. 1990-Oct. 1995
Assistant Professor, Department of Hematology, Medical College of Zhejiang University, Hangzhou, China
Nov. 1995-Oct.2000
Associate Professor/PhD Degree Candidate, Department of Hematology, Medical College of Zhejiang University, Hangzhou, China
Nov. 2000-present
Professor, Department of Hematology, Medical College of Zhejiang University, Hangzhou, China

Other Academic Experience
1992-1993 Visiting scholar, Department of Molecular Biology, University of Lübeck, Germany.
1999-2000 Visiting scholar, Department of Tumor and Hematology, Medical College of Humboldt University, Germany.
2004.9-11 Visiting professor, Bone Marrow Transplantation Center, in the Medical College of University of Tübingen, Germany.
2008.3-9 Visiting scholar, Department of lymphoma and myeloma, MD Anderson
Cancer Center, USA


Prize:
1. Project: Study on signal transduction and gene regulation of leukemia cell apoptosis induced by homoharringtonine and clinic significance.
The second class prize of Zhejiang Province Science and Technology Progress in 2003.
The first class prize of Zhejiang Province Health Technology Innovation in 2002.
2.Project: Unrelated donor allogeneic bone marrow transplantation.
The second class prize of National Science and Technology Progress in 2003.
The first class prize of Zhejiang Province Science and Technology Progress in 2002.
3.Project: Study on the mechanism and clinic treatment of myelodysplastic syndromes
The second class prize of Zhejiang Province Science and Technology progress in 2006.

Publications
1. He DH, Chen TY, Yang MJ, Zhu XH, Wang C, Cao X, Cai Z. Small Rab GTPase Rab7b promotes megakaryocytic differentiation by enhancing IL-6 production and STAT3-GATA-1 association. J Mol Med. 2011; 89 (2):137-150.
2. Bao HY, Lu PL, Li Y, Wang LJ, Li HY, He DH, Yang Y, Zhao Y, Yang L, Wang M, Yi Q, Cai Z. Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer Biol Ther. 2011; 11(1):58-67.
3. Luo Y, Zhao Y, Tan Y, Shi J, Han X, Zheng Y, Li L, He J, Xie W, Ye X, Cai Z, Lin M, Huang H. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia. Leuk Res. 2011 Feb 25. [Epub ahead of print]
4.Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, Wang M. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2010 Nov 1. [Epub ahead of print]
5. Zheng W, Guan M, Zhu L, Cai Z, Chung V, Huang H, Yen Y. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells. Anticancer Res. 2010 Jun;30(6):1921-30.
6. Xiao H, Cao W, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Meng X, Zheng W, Zheng G, Han X, Jin L, Zhang L, Wang Y, Yu X, Cai Z, Lin M, Ye X, Huang H. Immunosuppressive cytokine gene polymorphisms and outcome after related and unrelated hematopoietic cell transplantation in Chinese population. Biol Blood Marrow Transplant. 2010 May 7. [Epub ahead of print]
7. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009,114(17): 3625-3628.
8. Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, Huang H, Cai Z. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese Experience. Leuk Rec. 2009; 33(12) :1615-1618.
9. Shi JM, Cai Z, Huang H, Ye XJ, He JS, Xie WZ, Zhang J, Zhou XY, Luo Y, Lin Y, Li L, Zheng WY, Wei GQ, Lin MF. Role of CT-guided percutaneous lung biopsy in diagnosis of pulmonary fungal infection in patients with hematologic diseases. Int J Hematol. 2009; 89(5):624-627.
10.Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, Cai Z, Yi Q. Cyclin D1 as a universally
expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009; 23:1320-1328.
11. Yao M, Liu X, Li D, Chen T, Cai Z, Cao X. Late endosome/lysosome-localized Rab7b
suppresses TLR9-initiated proinflammatory cytokine and type I IFN production in macrophages. J Immunol. 2009; 183(3):1751-1758.
12. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor
effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009; 84(9):553-559.
13. Qiu L, He J, Ye X, Xie W, Shi J, Zheng W, Sun J, Zhu X, Cai Z, Huang H, Lin M. Invasive
pulmonary fungal infection accompanied by severe hemoptysis in patients with hematologic diseases: a report of nine cases. Int J Hematol. 2009 ,90(1):108-112.
14. Zhao Y, Liu L, Wang Y, Wu G, Lai X, Cao W, Luo Y, Tan Y, Shi J, Xie W, Ye X, Cai Z, Lin
M, Huang H. Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. Int J Hematol. 2009 ,89(4): 445 -451.
15. Bao HY, Wang LJ, Yang Y, Cai Z. TLR4 signals are involved in multiple myeloma cell proliferation and apoptosis. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 Sep;38(5):465-9. Chinese.
16. Hu J, He DH, XUE XK, Gao L, Wu WJ, Han XY, Cai Z. Homoharringtonine-induced apoptosis
of MDS cell line MUTZ-1 cells is mediated by the endoplastic reticulum stress pathway. Leukemia &Lymphoma. 2007; 48(5):964-977.
17. Wang Y Chen T, Han C, He D, Liu H, An H, Cai Z, Cao X. Lysosome-associated small Rab
GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4. Blood. 2007; 110(3): 962-971.
18. Xue X, Cai Z, Seitz G, Kanz L, Moehle R, Weisel K. Differential effects of G protein-coupled
receptors on hematopoietic progenitor cell growth depends on their signaling capacities. Ann N Y Acad Sci. 2007; 1106:180-181.
19. Xue XK, Sun WJ, Hu J, Yao HP, Cai Z. Influence on the immune function of the human
peripheral blood mononuclear cells transfected by retrovirus-mediated HSV-tk gene. Chin Med J. 2006 ;119(12):1038-1041.
20. Meng XJ, Lin MF, Cai Z. Relationship between the IFN-gamma producing cells specific for recipient and acute graft versus host disease. Zhonghua Xue Ye Xue Za Zhi. 2006 Feb;27(2):95-8. Chinese.
21. Bao HY, Cai Z. Expression of survivin mRNA in HHT-induced cell apoptosis of hematological malignancy cell lines. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 Mar;35(2):204-8. Chinese.
22. Wu WJ, Cai Z. Inhibition effect of fludarabine on the growth of myelodysplastic syndrome cell line MUTZ-1 and its mechanism. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 Mar;35(2):
136-42. Chinese.
23. Shi JM, Huang H, Cai Z, Luo Y, Ye XJ, Zhang J, Li L, He JS, Xie WZ, Zheng WY, Meng XJ,
Lin MF. Study on unrelated donor allogeneic bone marrow transplantation with Bu-CY2 conditioning regimen for myelodysplastic syndrome. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 Mar;35(2):122-6. Chinese.
24. Xie WZ, Lin MF, Huang H, Cai Z. Homoharringtonine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of telomerase. Am J Chin Med. 2006;34(2): 233-44.
25. Meng XJ, Lin MF, Cai Z. Detection, enrichment and expansion of T lymphocytes mediating alloresponse based on cytokine. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 Jan;35(1):39-44. Chinese.
26. Cai Z, Bao HY, Lin MF. Correlation between suvivin mRNA expression and homoharringtonine induced apoptosis of malignant hematopoietic cells. Chin Med J. 2005; 118(7):548-554.
27. Wei GQ, Lin MF, Huang H, Cai Z. Cytomegalovirus infection of myeloma cell line KM3 and its effect on IL-6 mRNA expression in the cells. Zhonghua Xue Ye Xue Za Zhi. 2004 Oct;25(10):596-9. Chinese.
28. Huang H, Cai Z, Lin MF, Xie WZ, Liang B, Li L, He JS, Luo Y, Zheng WY, Zhang J, Ye XJ, Hu XR, Chen SY, Jin AY. Treatment of childhood leukemia with unrelated donor allogeneic bone marrow transplantation. Zhonghua Er Ke Za Zhi. 2004 Nov;42(11):835-9. Chinese.
29. Lin MF, Xiong H, Cai Z, Wang YG. Study on the relationship between the inhibitors of apoptosis proteins and the apoptosis of myelodysplastic syndrome cell line cells induced by aclacinomycin in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Oct;12(5):606-9. Chinese.
30. Cen H, Lin MF, Huang H, Cai Z. Monocytic differentiation of bone marrow-derived hematopoietic precursors controlled by mesenchymal stem cell in absence of exogenous hematopoitic growth factors. Shi Yan Sheng Wu Xue Bao. 2004 Apr;37(2):139-44. Chinese.
31. Wei GQ, Lin MF, Huang H, Cai Z. Human cytomegalovirus protects multiple myeloma cell line KM3 cells from apoptosis induced by growth factor withdrawal. Chin Med J (Engl). 2004 Jun;117(6):903-7.
32. Huang WY, Cai Z, Sun WJ, Lu GH. The effects of mycophenolic acid on the maturation and immunologic function of murine bone marrow-derived dendritic cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Apr;12(2):207-12. Chinese.
33. Lin MF, Wei GQ, Huang H, Cai Z. Human cytomegalovirus induces alteration of beta-actin mRNA and microfilaments in human embryo fibroblast cells. J Zhejiang Univ Sci. 2004 Jun;5(6):733-7.
34. Cai Z, Bao HY, Ludwig WD, Wuchter C. Expression and significance of apoptosis protein inhibitor survivin and XIAP, in patients with myelodysplastic syndromes and in the cell line MUTZ-1. Zhonghua Xue Ye Xue Za Zhi. 2004 Jan;25(1):26-30. Chinese.
35. Liang B, Huang H, Cai Z, Xie WZ, Li L, He JS, Luo Y, Meng XJ, Zheng WY, Zhang J, Ye XJ, Hu XR, Chen SY, Jin AY, Lin MF. A comparison of clinical outcomes between HLA allele matched and 1 - 2 alleles mismatched unrelated allogeneic bone marrow transplantations. Zhonghua Xue Ye Xue Za Zhi. 2004 Feb;25(2):74-7. Chinese.
36. Tong HY, Lin MF, Xiong H, Cai Z. Inhibition effect of arsenic trioxide on the growth of human MDS cell line MUTZ-1 cells. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2004 Jan;33(1):68-72, 79. Chinese.
37. He JS, Huang H, Cai Z, Li L, Ye XJ, Zhang J, Hu XR, Jin AY, Lin MF. Treatment of one case of adult chronic myelogenous leukemia by two units of unrelated umbilical cord blood transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003 Oct;11(5):508-11. Chinese.
38. Sun WJ, Lin MF, Cai Z, Kellner U, Parwaresch R. Detection and analysis of bcl-1/IgH rearrangement in mantle cell lymphoma. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2002 Aug;31(4):239-244. Chinese.
39. Lin M, Meng X, Cai Z, Ye X. Expression and clinical significance of anti-apoptosis gene, survivin, in acute leukemia. Zhonghua Xue Ye Xue Za Zhi. 2002 May;23(5):251-3. Chinese.
40. Cai Z, Lin M, Wuchter C, Ruppert V, Dörken B, Ludwig WD, Karawajew L. Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia. 2001, 15:567-574.
41. Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dörken B, Ludwig WD, Karawajew L. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kB activity. Leukemia. 2001; 15: 921-918.

Active grant support
1 project title: The role and mechanism of bone marrow inflammatory cytokines in the relationship between fibroblasts and multiple myeloma
project origin: Major research plan of Chinese National Natural Science Foundation leader of the project
project outlay: 600,000
start stop time: 2011.1-2014.12
2 project title: The predicting significance of free light chain in myeloma
project origin: Ministry of Public Health leader of the project
project outlay: 250,000
start stop time: 2011.1-2014.123
3 project title: The mechanism of TLRs involved in immune evasion of multiple myeloma
project origin: Chinese National Natural Science Foundation leader of the project
project outlay: 320,000
start stop time: 2010.1-2012.12
4 project title: The establishment and clinical application of a new therapy mode of multiple myeloma based on risk stratification
project origin: Zhejiang Provincial Natural Science Foundation of China leader of the project
project outlay: 600,000
start stop time: 2010.1-2012.12
5 project title: The role of LPS induced signaling transduction pathway in the mechanism of TLR4 delection influencing acute GVHD
project origin: Ministry of Public Health and Zhejiang Province leader of the project
project outlay: 150,000
start stop time: 2010.1-2012.12
6 project title: The role of LPS induced signaling transduction pathway in the mechanism of TLR4 delection influencing acute GVHD
project origin: Ministry of Public Health and Zhejiang Province leader of the project
project outlay: 150,000
start stop time: 2010.1-2012.12
7 project title: The clinical study of multiple centers on the prognostic mode and standard therapy of multiple myeloma
project origin: Ministry of Public Health
project outlay: 300,000
start stop time: 2010.1-2012.12
8 project title: Natural immunological factor TLR4 in effective and mechanism of GVHD after BMT
project origin: Chinese National Natural Science Foundation leader of the project
project outlay: 300,000
start stop time: 2008.1.-2011.12
9 project title: Biological treatment for malignent tumor
project origin: Department of Health of Zhejiang Province leader of the project
project outlay: 300,000
start stop time: 2007.1.-2010.12
10 project title: cultivation program for Distinguished talented persons of Health of Zhejiang Province
project origin: Department of Health of Zhejiang Province
project outlay: 400,000
start stop time: 2007.7.-2012.6


Honors and Awards
1 Project: Study signal transduction and gene regulation of leukemia cell apoptosis
induced by Homoharringtonine and clinic significance.
The second class prize of Zhejiang Province Science and Technology Progress in 2003.
The first class prize of Zhejiang Province Health Technology Innovation in 2002
2 Project:Unrelated donor allogeneic bone marrow transplantation
The first class prize of National Science and Technology Progress in 2003.
The first class prize of Zhejiang Province Science and Technology Progress in 2002
3 Project: Study the mechinism and clinic treatment of Myelodysplastic Syndromes
The second class prize of Zhejiang Province Health Technology Innovation in 2005
The second class prize of Zhejiang Province Science and Technology progress in
2006
4 Project: The establishement and popularization of target therapy and newest allogeneic
stem cell transplantion strategy on chronic myeloid leukemia
The First class prize of Zhejiang Province Health Technology Innovation in 2010.

Editorials
1 Clinic therapeutics of general medicine
2 Modern ischemic cardiology
3 Progress in internal medicine
Research interest:
multiple myeloma, leukemia, lymphoma, new drug, microenvironment